Maarten Leyssen

2.1k total citations
31 papers, 1.0k citations indexed

About

Maarten Leyssen is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Maarten Leyssen has authored 31 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Epidemiology, 13 papers in Hepatology and 5 papers in Infectious Diseases. Recurrent topics in Maarten Leyssen's work include Hepatitis B Virus Studies (17 papers), Hepatitis Viruses Studies and Epidemiology (13 papers) and Hepatitis C virus research (10 papers). Maarten Leyssen is often cited by papers focused on Hepatitis B Virus Studies (17 papers), Hepatitis Viruses Studies and Epidemiology (13 papers) and Hepatitis C virus research (10 papers). Maarten Leyssen collaborates with scholars based in Belgium, United Kingdom and United States. Maarten Leyssen's co-authors include Bassem A. Hassan, Simon Reeve, Bart De Strooper, Jeanne‐Marie Jacquet, Derya Ayaz, Sébastien S. Hébert, Apiradee Theamboonlers, Yong Poovorawan, Voranush Chongsrisawat and Sherine Kuriyakose and has published in prestigious journals such as The EMBO Journal, Molecular Cell and Current Biology.

In The Last Decade

Maarten Leyssen

30 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maarten Leyssen Belgium 15 417 309 250 210 161 31 1.0k
Kenneth Cronin United States 9 238 0.6× 313 1.0× 267 1.1× 113 0.5× 151 0.9× 17 905
Hui Nie China 11 329 0.8× 307 1.0× 237 0.9× 63 0.3× 30 0.2× 29 915
C A Noonan United States 16 420 1.0× 255 0.8× 274 1.1× 148 0.7× 89 0.6× 20 1.5k
Christiane Héry France 16 548 1.3× 305 1.0× 361 1.4× 116 0.6× 54 0.3× 25 1.6k
Angelica Medina-Selby United States 13 201 0.5× 293 0.9× 182 0.7× 166 0.8× 46 0.3× 16 719
Carrie S. Dolman United States 17 410 1.0× 393 1.3× 71 0.3× 44 0.2× 146 0.9× 21 1.4k
Andrew Vaillant United States 25 1.5k 3.7× 531 1.7× 1.4k 5.5× 295 1.4× 67 0.4× 77 2.3k
André Pillez France 16 659 1.6× 510 1.7× 1.1k 4.3× 431 2.1× 61 0.4× 25 2.0k
Truus E. M. Abbink Netherlands 24 105 0.3× 1.3k 4.3× 43 0.2× 91 0.4× 117 0.7× 53 1.8k
B. Chevalier France 19 119 0.3× 575 1.9× 47 0.2× 94 0.4× 197 1.2× 64 1.3k

Countries citing papers authored by Maarten Leyssen

Since Specialization
Citations

This map shows the geographic impact of Maarten Leyssen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maarten Leyssen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maarten Leyssen more than expected).

Fields of papers citing papers by Maarten Leyssen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maarten Leyssen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maarten Leyssen. The network helps show where Maarten Leyssen may publish in the future.

Co-authorship network of co-authors of Maarten Leyssen

This figure shows the co-authorship network connecting the top 25 collaborators of Maarten Leyssen. A scholar is included among the top collaborators of Maarten Leyssen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maarten Leyssen. Maarten Leyssen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Watson‐Jones, Deborah, Hugo Kavunga‐Membo, Rebecca F. Grais, et al.. (2022). Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo. BMJ Open. 12(3). e055596–e055596. 13 indexed citations
2.
Bockstal, Viki, Maarten Leyssen, Dirk Heerwegh, et al.. (2022). Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola. npj Vaccines. 7(1). 156–156. 13 indexed citations
3.
Bockstal, Viki, Auguste Gaddah, Neil Goldstein, et al.. (2021). Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen. npj Vaccines. 6(1). 157–157. 8 indexed citations
4.
5.
Langley, Joanne M., Naresh Aggarwal, Scott A. Halperin, et al.. (2016). A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant. The Journal of Infectious Diseases. 215(1). 24–33. 53 indexed citations
6.
7.
Khatami, Ameneh, Matthew D. Snape, Clarissa Oeser, et al.. (2013). Phase II Study of a Three-dose Primary Vaccination Course of DTPa-IPV/Hib-MenC-TT Followed by a 12-month Hib-MenC-TT Booster in Healthy Infants. The Pediatric Infectious Disease Journal. 32(6). 675–681. 3 indexed citations
8.
Haddad, Dominik, Sven Vilain, Melissa Vos, et al.. (2013). Mutations in the Intellectual Disability Gene Ube2a Cause Neuronal Dysfunction and Impair Parkin-Dependent Mitophagy. Molecular Cell. 50(6). 831–843. 64 indexed citations
9.
10.
11.
Damme, Pierre Van, et al.. (2011). Long-term Immunogenicity and Immune Memory After Two Doses of the Adult Formulation of a Combined Hepatitis A and B Vaccine in Children 1 to 11 Years of Age. The Pediatric Infectious Disease Journal. 30(8). 703–705. 8 indexed citations
12.
Damme, Pierre Van, et al.. (2010). Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study. BMC Infectious Diseases. 10(1). 357–357. 22 indexed citations
13.
Marshall, Helen, Terry Nolan, Javier Díez‐Domingo, et al.. (2010). Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1–11 years. Vaccine. 28(27). 4411–4415. 11 indexed citations
14.
15.
Poovorawan, Yong, Voranush Chongsrisawat, Apiradee Theamboonlers, et al.. (2010). Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. Journal of Viral Hepatitis. 18(5). 369–375. 78 indexed citations
16.
Poovorawan, Yong, Voranush Chongsrisawat, Apiradee Theamboonlers, et al.. (2009). Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine. 28(3). 730–736. 91 indexed citations
17.
Damme, Pierre Van, Frank von Sonnenburg, Christoph Hatz, et al.. (2009). Long‐term immunogenicity of preservative‐free hepatitis B vaccine formulations in adults. Journal of Medical Virology. 81(10). 1710–1715. 5 indexed citations
18.
Surquin, Murielle, Christian Tielemans, Péter Vörös, et al.. (2009). Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02V-adjuvanted hepatitis B vaccine. Kidney International. 77(3). 247–255. 30 indexed citations
19.
Leyssen, Maarten & Bassem A. Hassan. (2007). A fruitfly's guide to keeping the brain wired. EMBO Reports. 8(1). 46–50. 15 indexed citations
20.
Damme, Philip Van, Maarten Leyssen, Geert Callewaert, Wim Robberecht, & Ludo Van Den Bosch. (2003). The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neuroscience Letters. 343(2). 81–84. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth Cronin Breakdown of academic impact, for papers by Hui Nie Breakdown of academic impact, for papers by C A Noonan Breakdown of academic impact, for papers by Christiane Héry Breakdown of academic impact, for papers by Angelica Medina-Selby Breakdown of academic impact, for papers by Carrie S. Dolman Breakdown of academic impact, for papers by Andrew Vaillant Breakdown of academic impact, for papers by André Pillez Breakdown of academic impact, for papers by Truus E. M. Abbink Breakdown of academic impact, for papers by B. Chevalier
Rankless by CCL
2026